What It Is
IGF-1 LR3, also called Long R3 IGF-I, is a synthetic analog of human insulin-like growth factor 1 described in the literature as an 83-amino-acid molecule carrying an arginine-related substitution at position 3 and an extended structure compared with native IGF-1.[1] Native IGF-1 is an endogenous hormone involved in cell growth and metabolism; IGF-1 LR3 is a laboratory-engineered variant of it, not interchangeable with it.
IGF-1 LR3 is also frequently confused with mecasermin, the only FDA-approved recombinant human IGF-1 drug, and with IGF-1 DES, a different truncated IGF-1 analog. All three belong to the same growth-factor family but differ in structure, evidence base, and regulatory status.
How It Works
IGF-1 LR3 is designed to retain activity at the IGF-1 receptor, a receptor tyrosine kinase that triggers signaling pathways such as PI3K-Akt and MAPK involved in cell proliferation, protein synthesis, and glucose handling.[9] Its defining laboratory feature is reduced affinity for IGF-binding proteins — the carrier proteins that normally limit how much IGF-1 is free to act on tissue — a property associated with enhanced potency in experimental systems.[1]
Because the IGF-1 and insulin receptor systems overlap, IGF-1 LR3 activity is mechanistically tied to both growth signaling and blood glucose regulation. A measurable effect in a cultured cell or animal model shows the pathway can be activated; it does not demonstrate a safe or beneficial effect in a person.
What the Research Shows
Direct human clinical research on IGF-1 LR3 as a therapeutic agent is limited, and no FDA-approved label defines an indication, dosing regimen, or safety profile for it. Most of what is published comes from cell-culture and animal studies of receptor binding, potency, and tissue growth — useful for understanding mechanism but not for establishing human efficacy or safety.[13][14]
Claims that IGF-1 LR3 builds muscle, accelerates tissue repair, or reduces body fat in humans rely on extrapolation from IGF-1 pathway biology in muscle hypertrophy research, not on controlled human trials of IGF-1 LR3 itself. The one human clinical-evidence base in this drug family belongs to mecasermin, which has demonstrated increased growth velocity in children with severe primary IGF-1 deficiency — a distinct molecule, population, and indication that does not transfer to IGF-1 LR3.
Safety & Side Effects
Because IGF-1 LR3 has no FDA-approved prescribing label, its side-effect profile in humans is not formally characterized. Safety concerns are inferred from IGF-1 pathway biology and mecasermin's approved label, which lists several risks relevant to any IGF-1 receptor agonist:
- Hypoglycemia, due to insulin-like effects on blood glucose
- Intracranial hypertension and lymphoid tissue hypertrophy
- Orthopedic complications such as slipped capital femoral epiphysis and scoliosis progression
- Hypersensitivity reactions
- Neoplasia-related warnings, reflecting the IGF-1 receptor's role in cell proliferation and survival pathways tied to cancer biology
These are label findings for a related but different drug, not confirmed IGF-1 LR3 outcomes, but they show why growth-factor pathway agents are not low-risk. People with diabetes, cancer history, or pregnancy face particular uncertainty given the absence of IGF-1 LR3-specific human safety data.
Regulatory Status
IGF-1 LR3 is not FDA-approved as a medicine and has no approved therapeutic indication.[2] The related, approved drug in this pathway is mecasermin (Increlex), reserved for pediatric patients with severe primary IGF-1 deficiency or growth hormone gene deletion with neutralizing antibodies to growth hormone — a different, narrowly indicated product that does not validate IGF-1 LR3 for any use.[3]
Compounded or unapproved peptide products, including IGF-1 LR3 sold outside regulated pharmacy channels, are not reviewed by the FDA for identity, sterility, potency, or manufacturing quality before reaching consumers.[18] IGF-1 and its analogues also appear on the World Anti-Doping Agency's Prohibited List, relevant to performance-related claims but separate from medical safety approval.[19]